⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51621 | 1.00 | — | — | |
| SCHEMBL6934580 | 1.00 | — | — | |
| SCHEMBL25443681 | 0.96 | — | — | |
| SCHEMBL17379548 | 0.83 | CHRM2 (0.35) | — | |
| SCHEMBL17379528 | 0.83 | CHRM2 (0.35) | — | |
| SCHEMBL17379281 | 0.83 | CHRM2 (0.35) | — | |
| SCHEMBL6052755 | 0.78 | — | — | |
| SCHEMBL10314719 | 0.78 | — | — | |
| SCHEMBL10314713 | 0.78 | — | — | |
| SCHEMBL13949952 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540157-B2 | Oxysterols and methods of use thereof | Sage Therapeutics, LLC (US) | 2026-02-03 | — | — | US | disclosed |
| CN-119350419-A | Oxysterol and methods of use thereof | 萨奇治疗股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368214-A1 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-114478677-B | Oxysterol and methods of use thereof | 萨奇治疗股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4392432-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199682-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11851457-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS (US) | 2023-12-26 | — | — | US | disclosed |
| EP-4252848-A2 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111819173-B | CD73 inhibitors | 伊莱利利公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3529257-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-1999036400-A1 | METHOD OF PREPARATION OF CHOLECALCIFEROL DERIVATIVES AND NEW INTERMEDIATE COMPOUNDS | INSTYTUT FARMACEUTYCZNY (PL) | 1999-07-22 | — | — | WO | disclosed |
| WO-1996038465-A1 | ALKYL 2β-MORPHOLINO-ANDROSTANE DERIVATIVES | AKZO NOBEL N.V. (NL) | 1996-12-05 | — | — | WO | disclosed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |